Heart disease is the leading cause of death in the United States, and excess weight is one of its biggest drivers. For years, doctors knew that losing weight could help the heart, but no weight loss medicine had been proven to prevent heart attacks or strokes in people without diabetes.
That changed with the SELECT trial. This landmark study showed that Semaglutide, the active ingredient in Wegovy and Ozempic, can lower the risk of serious heart problems in adults with obesity or overweight and existing heart disease.
In this guide, we explain the semaglutide heart benefits: what the SELECT trial found, how Semaglutide may protect the heart, who may qualify, and what to discuss with your doctor.
The link between obesity and heart disease
The connection between obesity and heart disease is strong. Carrying extra weight, especially around the belly, can lead to:
- High blood pressure
- High cholesterol and triglycerides
- Insulin resistance and type 2 diabetes
- Ongoing inflammation in the blood vessels
- Extra strain on the heart, which can lead to heart failure
All of these raise your heart disease risk, including the risk of heart attack and stroke. That’s why researchers wanted to know whether a powerful weight loss medicine could do more than help people lose weight. Could it actually protect the heart?
What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist. It mimics a natural gut hormone that helps control appetite and blood sugar. It’s sold as:
- Wegovy – a once-weekly injection (2.4 mg) for chronic weight management and heart risk reduction
- Ozempic – a once-weekly injection for type 2 diabetes
- Rybelsus – a daily tablet for type 2 diabetes
What was the SELECT trial?
SELECT (Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity) was one of the largest heart studies ever done with a weight-loss medication. Results were published in the New England Journal of Medicine in 2023.
Who was in the study?
- 17,604 adults aged 45 and older
- A body mass index (BMI) of 27 or higher (overweight or obesity)
- Existing heart disease, such as a past heart attack, stroke, or peripheral artery disease
- No diabetes, which made this study unique
Participants received either semaglutide 2.4 mg (the Wegovy dose) or a placebo once a week, along with standard heart care such as statins and blood pressure medicines. They were followed for an average of about 3.3 years.
SELECT trial results: Semaglutide heart benefits explained
The main goal was to see whether Semaglutide reduced major adverse cardiovascular events (MACE), meaning heart attack, stroke, or death from heart disease.
The headline result: 20% lower risk
People taking Semaglutide had a 20% lower risk of a heart attack, stroke, or heart-related death compared with placebo.
| Outcome | Semaglutide | Placebo |
| Major heart events (heart attack, stroke, or heart-related death) | 6.5% | 8.0% |
| Average weight loss | About 9.4% | About 0.9% |
Breaking down the results
- Heart attacks: about 28% fewer non-fatal heart attacks
- Death from any cause: about 19% lower risk
- Heart failure events: fewer hospital visits and urgent care for heart failure
- Strokes and heart-related deaths: these trended lower, but the differences on their own were not strong enough to be statistically certain
Benefits beyond the numbers
Semaglutide also improved several heart risk factors, including blood pressure, waist size, cholesterol levels, and C-reactive protein (CRP), an inflammation marker.
How does Semaglutide protect the heart?
Researchers are still studying exactly how GLP-1 heart protection works, but several effects likely play a role:
- Weight loss: Less body weight means less strain on the heart and blood vessels.
- Lower blood pressure: Even a small drop in blood pressure reduces the risk of heart attack and stroke.
- Reduced inflammation: Lower CRP levels suggest calmer, healthier blood vessels.
- Better cholesterol and blood sugar: Improved triglycerides and blood sugar help slow plaque buildup in the arteries.
- Direct effects on blood vessels: GLP-1 receptors are found in the heart and blood vessels, and Semaglutide may directly protect them.
Interestingly, the heart benefits in SELECT appeared early, before much weight had been lost, and were seen across different amounts of weight loss. This suggests Semaglutide’s cardiovascular benefits come from more than weight loss alone.
FDA approval for heart risk reduction
Based on the SELECT results, the FDA approved Wegovy in March 2024 to reduce the risk of heart attack, stroke, and heart-related death in adults with established heart disease and either obesity or overweight. Wegovy became the first weight loss medicine approved to help prevent life-threatening heart problems.
This approval is also important for insurance. Wegovy now has a heart-related use; Medicare and some other plans may cover it for eligible patients with heart disease, even though they may not cover weight loss drugs in general.
What about Semaglutide for people with diabetes?
The semaglutide cardiovascular benefits aren’t limited to people without diabetes. Earlier trials showed heart protection in people with type 2 diabetes too:
- SUSTAIN-6 (Ozempic): about a 26% lower risk of major heart events in people with type 2 diabetes and high heart risk.
- SOUL (oral Semaglutide): the daily tablet lowered major heart events by about 14% in people with type 2 diabetes and heart or kidney disease.
- FLOW (Ozempic): in people with type 2 diabetes and kidney disease, Semaglutide slowed kidney decline and also reduced heart-related deaths.
Who may benefit from Semaglutide for heart health?
You may be a candidate for Wegovy’s heart benefits if you:
- Are an adult with a BMI of 27 or higher
- Have known heart disease, such as a past heart attack, stroke, stent, bypass surgery, or peripheral artery disease
Semaglutide is not a replacement for your other heart medicines. In SELECT, most participants were also taking statins, blood pressure medicines, and blood thinners. Semaglutide was added on top of that care.
Side effects and safety
Semaglutide’s side effects are mostly digestive, especially when starting or increasing the dose:
- Nausea, vomiting, diarrhea, or constipation
- Stomach pain or bloating
- Tiredness
In SELECT, about 17% of people on Semaglutide stopped treatment because of side effects, compared with about 8% on placebo, mainly due to stomach problems.
Serious but less common risks include pancreatitis, gallbladder problems, kidney problems from dehydration, and low blood sugar when combined with insulin or sulfonylureas. Semaglutide also has a boxed warning about thyroid C-cell tumors. Don’t use it if you or a family member has had medullary thyroid carcinoma (MTC) or MEN 2.
Heart medicines
Semaglutide works best as part of a complete heart care plan. Your doctor may also prescribe medicines to manage cholesterol, blood pressure, and clotting. At PremiumRxDrugs, you can explore trusted options such as:
- Lipitor 20 mg (atorvastatin) – a statin that lowers LDL (“bad”) cholesterol and reduces heart attack and stroke risk
- Atorvastatin 40 mg – an affordable generic statin for cholesterol control
- Rozavel (rosuvastatin) – a high-strength statin for lowering cholesterol
- Losartan 50 mg – an ARB that lowers blood pressure and protects the heart and kidneys
- Norvasc 10 mg (amlodipine) – a calcium channel blocker for high blood pressure and chest pain
- Metolar XR (metoprolol succinate) – a beta-blocker often used after a heart attack and for heart failure
- Deplatt 75 mg (clopidogrel) – an antiplatelet medicine that helps prevent blood clots after a heart attack or stent
Browse our full range of heart and blood pressure medicines and anticoagulants. All prescription medicines require a valid prescription; discuss the best medicine, dosage, and treatment duration with your doctor for best results.
Frequently Asked Questions
1. Does Ozempic help the heart too, or only Wegovy?
Both contain Semaglutide. Ozempic is FDA-approved to lower the risk of heart attack, stroke, and heart-related death in adults with type 2 diabetes and heart disease. Wegovy is approved for the same purpose in adults with heart disease and overweight or obesity, with or without diabetes.
2. Do I need to have heart disease to get the heart benefits?
The SELECT trial only studied people who already had heart disease, so the FDA-approved heart use of Wegovy applies to that group. Semaglutide may still improve heart risk factors like weight and blood pressure in other people, but its effect on preventing a first heart attack hasn’t been proven in the same way.
3. How long does it take for Semaglutide to protect the heart?
In SELECT, the difference in heart events between Semaglutide and placebo started to appear within the first few months of treatment and grew over time. This early benefit suggests Semaglutide helps the heart in ways beyond weight loss alone.
4. Can I stop my statin or blood pressure medicine if I take Semaglutide?
No. Semaglutide is meant to be added to your current heart care, not replace it. Never stop or change your heart medicines without talking to your doctor.
5. Does Semaglutide help with heart failure?
Studies suggest it may. In SELECT, fewer people on Semaglutide had heart failure events. Other trials found that Semaglutide improved symptoms, physical function, and quality of life in people with obesity and a common type of heart failure called HFpEF (heart failure with preserved ejection fraction).
The bottom line
The SELECT trial changed how doctors think about obesity and heart disease. It showed that Semaglutide can lower the risk of heart attack, stroke, and heart-related death by about 20% in adults with overweight or obesity and existing heart disease, even without diabetes. These heart benefits of Semaglutide, combined with healthy habits and standard heart medicines, offer a powerful new way to protect your heart. Talk to your doctor to see if it’s right for you.
Disclaimer: This article is for informational purposes only and is not medical advice. Always consult a licensed healthcare provider before starting, stopping, or changing any medication.
Latest posts by Marie (see all)
- Can Semaglutide Reduce Heart Disease Risk? SELECT Trial Results Explained - November 5, 2026
- Semaglutide FAQs: 15 Expert Answers Every New Patient Should Know - October 31, 2026
- Alzheimer’s Disease Treatment: Medications That May Help Slow Memory Loss - October 29, 2026
